Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Simon Anders
    Senior Member
    • Feb 2010
    • 995

    #16
    Originally posted by vebaev View Post
    What about these genes that are 0 reads in one group and non-zero in the other group? I got =+Inf ot =-Inf? Should I took tham or discard them from the most diff.altered table?
    Thanks
    If you have 0 counts in one condition and hundreds of counts in other, this is most likely a valid signal, and DESeq should indicate this with a small p value. Of course, the fold change estimate is not to useful but that is a general problem if one of conditions has very low counts

    Comment

    • vebaev
      Senior Res.
      • Oct 2008
      • 112

      #17
      Yes Simon,
      the =Inf are coming from rows where one of the groups are 0 and other is some reads (sometimes 5 simetimes 500)

      I also found your post in other topic about these =Inf that if the last 2 columns the values are too big or close to zero I should discard these rows from further analysis?
      Last edited by vebaev; 08-19-2011, 12:43 AM.
      ------------
      SMART - bioinfo.uni-plovdiv.bg

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      23 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      27 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-13-2026, 09:56 AM
      0 responses
      23 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-09-2026, 11:14 AM
      0 responses
      28 views
      0 reactions
      Last Post SEQadmin2  
      Working...